CDC Recommendations
SHINGRIX: Recommended by the CDC for the prevention of shingles1,*
The CDC states SHINGRIX is1:
![]() |
Recommended for the prevention of herpes zoster and related complications for immunocompetent adults aged ≥50 years |
![]() |
Recommended for the prevention of herpes zoster and related complications for immunocompetent adults who previously received zoster vaccine live (ZVL) |
![]() |
Preferred over ZVL for the prevention of herpes zoster and related complications |
Please see Important Considerations below.
2018 CDC Recommendations: Important Considerations Related to Alternate Dosing, Concomitant Use, Patients Previously Vaccinated With ZVL, and Persons With a Prior History of Herpes Zoster
Alternate Dosing
This article contains dosing schedule information that is inconsistent with the label. According to the Prescribing Information for SHINGRIX, 2 doses (0.5 mL each) should be administered intramuscularly according to the following schedule: A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later.2
Concomitant Use
SHINGRIX was administered concomitantly with FLUARIX QUADRIVALENT (Influenza Vaccine) in an open-label clinical study of subjects 50 years and older (N=828). There was no evidence of interference in the immune response to any of the antigens contained in SHINGRIX or the coadministered vaccine.2
Patients Previously Vaccinated With ZVL
- There are limited data on vaccination with SHINGRIX in patients previously vaccinated with ZVL compared to those not previously vaccinated with ZVL3
- In a phase 3 study, humoral immunogenicity was non-inferior among subjects previously vaccinated at least 5 years earlier with ZVL
- No apparent safety differences were observed between study groups within 30 days post-dose 2 of SHINGRIX
- Solicited local and systemic symptoms were similar between study groups
- The levels of antibodies and immune cells that correlate with protection against shingles have not been clearly defined
Persons With a Prior History of Herpes Zoster
The pivotal clinical trials for SHINGRIX excluded patients with a prior history of herpes zoster.2
You may also be interested in:
See how you and your staff can reconstitute SHINGRIX in four steps. Vaccinate confidently.
Talk to your patients about what to expect, including common adverse reactions.
- †Data from the phase 3 ZOE-50 (≥50 years of age) trial and pooled data in individuals ≥70 years of age from the phase 3 ZOE-50 and ZOE-70 trials from subjects who received 2 doses of SHINGRIX (N=7344 and 8250, respectively) or placebo (N=7415 and 8346, respectively) and did not develop a confirmed case of herpes zoster within 1 month after the second dose. See study designs on Efficacy page for more details.2
References: 1. Centers for Disease Control and Prevention. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. MMWR. 2018;67(3):103-108. 2. Prescribing Information for SHINGRIX. 3. Grupping K, Campora L, Douha M, et al. Immunogenicity and safety of the HZ/su adjuvanted herpes zoster subunit vaccine in adults previously vaccinated with a live attenuated herpes zoster vaccine. J Infect Dis. 2017;216(11):1343-1351.
Trademarks are property of their respective owners.